Phase 2 trial of single agent docetaxel in platinum and paclitaxel-refractory ovarian cancer, fallopian tube cancer, and primary carcinoma of the peritoneum

By Markman M.   Zanotti K.   Webster K.   Peterson G.   Kulp B.   Belinson J.  

Gynecologic Oncology, Vol. 91, Iss. 3, 2003-12 ,pp. : 573-576

Elsevier

Access to resources Recommend Favorite

Phase 2 trial of single-agent gemcitabine in platinum-paclitaxel refractory ovarian cancer

By Markman M.   Webster K.   Zanotti K.   Kulp B.   Peterson G.   Belinson J.  

Gynecologic Oncology, Vol. 90, Iss. 3, 2003-09 ,pp. : 593-596

Elsevier

Access to resources Recommend Favorite

Phase 2 Trial of Single Agent Ifosfamide/Mesna in Patients with Platinum/Paclitaxel Refractory Ovarian Cancer Who Have Not Previously Been Treated with an Alkylating Agent

By Markman M.   Kennedy A.   Sutton G.   Hurteau J.   Webster K.   Peterson G.   Kulp B.   Belinson J.  

Gynecologic Oncology, Vol. 70, Iss. 2, 1998-08 ,pp. : 272-274

Elsevier

Access to resources Recommend Favorite

Phase 2 Evaluation of Topotecan Administered on a 3-Day Schedule in the Treatment of Platinum- and Paclitaxel-Refractory Ovarian Cancer

By Markman M.   Kennedy A.   Webster K.   Kulp B.   Peterson G.   Belinson J.  

Gynecologic Oncology, Vol. 79, Iss. 1, 2000-10 ,pp. : 116-119

Elsevier

Access to resources Recommend Favorite

A phase I trial of high-dose paclitaxel, cyclophosphamide and mitoxantrone with autologous blood stem cell support for the treatment of metastatic breast cancer

By Gluck S.   Germond C.   Lopez P.   Cano P.   Dorreen M.   Koski T.   Arnold A.   Dulude H.   Gallant G.  

European Journal of Cancer, Vol. 34, Iss. 7, 1998-06 ,pp. : 1008-1014

Elsevier

Access to resources Recommend Favorite